News | Artificial Heart | January 30, 2025

Realheart TAH Receives Humanitarian Use Device Designation from FDA

Realheart TAH is a total artificial heart that mimics the structure and physiological function of the human heart.


Jan. 29, 2025 – Scandinavian Real Heart AB (recently aannounced that its total artificial heart, Realheart TAH, has been granted Humanitarian Use Device (HUD) designation by the U.S. Food and Drug Administration (FDA). The HUD designation makes Realheart TAH eligible to apply for Humanitarian Device Exemption (HDE), an expedited regulatory pathway that can grant the product limited marketing rights.

Realheart TAH is a total artificial heart that mimics the structure and physiological function of the human heart. Following multiple rounds of communication with the FDA, the device has been granted Humanitarian Use Device status which paves the way for Realheart TAH to treat patients with advanced biventricular heart failure who have few other options and need to be supported by a total artificial heart.

HDE is approved if the sponsor can demonstrate data indicating probable safety and benefit to the intended patient group.

Realheart will continue communications with the FDA to develop a clinical investigation strategy to support a Humanitarian Device Exemption premarket approval.

“We are extremely pleased that Realheart® TAH has been granted Humanitarian Use Device designation by the FDA. It is gratifying to look forward to our efforts culminating in such humanitarian benefit. We look forward to updating the market on further clinical and regulatory activities and meanwhile continue our preclinical development which will be important for a potential future full market approval,” says Ina Laura Perkins, CEO of Realheart.

For more information, visit www.realheart.se

 


Related Content

News | Artificial Heart

November 20, 2023 — Student engineers from the University of Bath are on top of the world after winning an international ...

Home November 20, 2023
Home
News | Artificial Heart

November 10, 2023 — BiVACOR, a clinical-stage medical device company developing the Total Artificial Heart (TAH), has ...

Home November 10, 2023
Home
Feature | Artificial Heart | By Francisco Arabia, MD, MBA

The U.S. organ donation system has long been under scrutiny, with questions about fairness in organ allocation and ...

Home July 20, 2023
Home
News | Artificial Heart

July 3, 2023 — Nearly one-third of patients with an implanted device to prevent sudden death have anxiety in the first ...

Home July 03, 2023
Home
News | Artificial Heart

May 1, 2023 — Picard Medical, Inc. (“Picard Medical”), the parent company of SynCardia Systems, LLC (“SynCardia”), a ...

Home May 01, 2023
Home
News | Artificial Heart

April 4, 2023 — A team at the Technical University of Munich (TUM) has induced stem cells to emulate the development of ...

Home April 04, 2023
Home
News | Artificial Heart

March 17, 2023 — More donated hearts could be suitable for transplantation if they are kept functioning within the body ...

Home March 17, 2023
Home
News | Artificial Heart

February 17, 2023 — Allegheny Health Network’s (AHN) Cardiovascular Institute reached a significant milestone in cardiac ...

Home February 17, 2023
Home
News | Artificial Heart

August 15, 2022 — Researchers in the Biomedical Engineering Department at UConn have developed a new cardiac cell ...

Home August 15, 2022
Home
News | Artificial Heart

July 14, 2022 — University of Toronto Engineering researchers have grown a small-scale model of a human left heart ...

Home July 14, 2022
Home
Subscribe Now